Catalogue des documents juridiques (cjeu_case)

104 315 documents
25401

Judgment of the General Court (Fourth Chamber) of 26 January 2022.#Kedrion SpA v European Medicines Agency.#Access to documents – Regulation (EC) No 1049/2001 – Collection and processing of plasma – Plasma master file – Refusal to grant access – Exception relating to the protection of the commercial interests of a third party – Incorrect determination of the subject matter of the application – Obligation to base the refusal to grant access on specific and concrete reasons.#Case T-570/20.

cjeu_case ·
25402

Judgment of the General Court (Fourth Chamber) of 26 January 2022.#Kedrion SpA v European Medicines Agency.#Access to documents – Regulation (EC) No 1049/2001 – Collection and processing of plasma – Plasma master file – Refusal to grant access – Exception relating to the protection of the commercial interests of a third party – Incorrect determination of the subject matter of the application – Obligation to base the refusal to grant access on specific and concrete reasons.#Case T-570/20.

cjeu_case ·
25405

Judgment of the General Court (Sixth Chamber) of 26 January 2022.#Unger Marketing International LLC v European Union Intellectual Property Office.#Community design – Invalidity proceedings – Design representing a water purifier – Ground for invalidity – Non-compliance with requirements for protection – Article 25(1)(b) of Regulation (EC) No 6/2002 – Features of appearance of a product solely dictated by its technical function – Article 8(1) of Regulation No 6/2002 – Declaration of invalidity.#Case T-325/20.

cjeu_case ·
25406

Judgment of the General Court (Sixth Chamber) of 26 January 2022.#Unger Marketing International LLC v European Union Intellectual Property Office.#Community design – Invalidity proceedings – Design representing a water purifier – Ground for invalidity – Non-compliance with requirements for protection – Article 25(1)(b) of Regulation (EC) No 6/2002 – Features of appearance of a product solely dictated by its technical function – Article 8(1) of Regulation No 6/2002 – Declaration of invalidity.#Case T-325/20.

cjeu_case ·
25410

Case T-325/20: Judgment of the General Court of 26 January 2022 — Unger Marketing International v EUIPO — Orben Wasseraufbereitung (Water purifiers) (Community design — Invalidity proceedings — Design representing a water purifier — Ground for invalidity — Non-compliance with requirements for protection — Article 25(1)(b) of Regulation (EC) No 6/2002 — Features of appearance of a product solely dictated by its technical function — Article 8(1) of Regulation No 6/2002 — Declaration of invalidity)

cjeu_case ·
25414

Judgment of the General Court (Ninth Chamber) of 26 January 2022.#Mylan IRE Healthcare Ltd v European Commission.#Medicinal products for human use – Orphan medicinal products – Marketing authorisations for the medicinal products Tobramycin VVB and associated names – Derogation from the market exclusivity of Tobi Podhaler, containing the active substance tobramycin – Article 8(3)(c) of Regulation (EC) No 141/2000 – Concept of ‘significant benefit’ – Concept of ‘clinical superiority’ – Article 3(2) and (3)(d) of Regulation (EC) No 847/2000 – Duty of care – Manifest error of assessment.#Case T-303/16.

cjeu_case ·
25415

Judgment of the General Court (Ninth Chamber) of 26 January 2022.#Mylan IRE Healthcare Ltd v European Commission.#Medicinal products for human use – Orphan medicinal products – Marketing authorisations for the medicinal products Tobramycin VVB and associated names – Derogation from the market exclusivity of Tobi Podhaler, containing the active substance tobramycin – Article 8(3)(c) of Regulation (EC) No 141/2000 – Concept of ‘significant benefit’ – Concept of ‘clinical superiority’ – Article 3(2) and (3)(d) of Regulation (EC) No 847/2000 – Duty of care – Manifest error of assessment.#Case T-303/16.

cjeu_case ·
25416

Case T-303/16: Judgment of the General Court of 26 January 2022 — Mylan IRE Healthcare v Commission (Medicinal products for human use — Orphan medicinal products — Marketing authorisations for the medicinal products Tobramycin VVB and associated names — Derogation from the market exclusivity of Tobi Podhaler, containing the active substance tobramycin — Article 8(3)(c) of Regulation (EC) No 141/2000 — Concept of ‘significant benefit’ — Concept of ‘clinical superiority’ — Article 3(2) and (3)(d) of Regulation (EC) No 847/2000 — Duty of care — Manifest error of assessment)

cjeu_case ·
25417

Judgment of the General Court (Fourth Chamber, Extended Composition) of 26 January 2022.#Intel Corporation Inc. v European Commission.#Competition – Abuse of dominant position – Microprocessors market – Decision finding an infringement of Article 102 TFEU and Article 54 of the EEA Agreement – Loyalty rebates – ‘Naked’ restrictions – Characterisation as abuse – As-efficient competitor analysis – Overall strategy – Single and continuous infringement.#Case T-286/09 RENV.

cjeu_case ·
25418

Judgment of the General Court (Fourth Chamber, Extended Composition) of 26 January 2022.#Intel Corporation Inc. v European Commission.#Competition – Abuse of dominant position – Microprocessors market – Decision finding an infringement of Article 102 TFEU and Article 54 of the EEA Agreement – Loyalty rebates – ‘Naked’ restrictions – Characterisation as abuse – As-efficient competitor analysis – Overall strategy – Single and continuous infringement.#Case T-286/09 RENV.

cjeu_case ·